#INMB
Inmune Bio ($INMB) – 13G holder update

• Holder: Highbridge Capital Management
• Stake: now 4.98% (about $2M)
• Note: counts convertible securities
• Filed: Nov 16 · Schedule 13G/A

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#Investing #Stocks
Highbridge Capital Management LLC: 4.98% of Inmune Bio ($INMB)
Schedule 13G/A filed Nov 16. Who filed, the stake, and how it changed.
elixstocks.com
November 16, 2026 at 1:48 PM
I looked at the business behind $INMB (Inmune Bio, Inc.) for you. Based on financial data and reported results.

At what market price would buying or selling $INMB make sense to you?

#INMB
November 13, 2026 at 12:26 AM
#$OGEN gets NYSE compliance extension to Feb 2028, removing delisting risk. Balance sheet issues remain; equity solutions needed. #$CADL #$KTTA #$NPCE #$PMN #$VIR #$CALC #$INMB #$NIVF #$BBLG

www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 11/13/26
export-download.canva.com
November 13, 2026 at 1:40 PM
🚨 $INMB
On October 28, 2026, the Company issued a press release announcing the pricing of the Offering.
SEC Filing: INMB
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 11:41 AM
🚨 JUST IN: $INMB
INmune Bio submits Ebstrocel pre-MAA to UK MHRA, targets approval in mid-2027

#SEC #stocks #investing #INMB #Regulatory
🔗 secwatch.observer
October 21, 2026 at 1:07 PM
🚨 $INMB
INmune Bio Inc. has prepared a slide deck that the Company intends to use in presentations from time to time . The Presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.3 of this Current Report on Form 8-K is furnish...
SEC Filing: INMB
Click to view the official SEC document.
www.sec.gov
October 21, 2026 at 1:01 PM
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
INmune Bio (INMB) submitted its final UK pre-application package for Ebstrocel to the MHRA on October 20, 2026. The investigational cell therapy targets recessive dystrophic epidermolysis bullosa (RDEB). The company targets a complete marketing application in early February 2027, replacing a rolling submission previously planned to start in late 2026.INmune Bio believes faster manufacturing progress supports a revised approach that could advance potential UK approval by approximately six weeks to mid-2027, subject to MHRA review. It expects a response within three to six months after submission, subject to validation, review and additional information requests. A U.S. biologics license application is planned for Q2 2027, subject to feedback from a planned FDA Type B meeting; the company is prioritizing the FDA application ahead of an EMA submission.
www.stocktitan.net
October 21, 2026 at 11:15 AM
$INMB — Press Release

INmune Bio disclosed via two press releases and a slide deck (furnished under Reg FD) that it has signed a Master Services Agreement with Uniphar Durbin Ireland Limited to support international access, distribution and commercialization of Ebstrocel™ (CORDStr...

🧵 continued ↓
October 21, 2026 at 4:32 PM
#INMB INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

https://www.stocktitan.net/news/INMB/i-nmune-bio-establishes-global-commercialization-framework-for-5j7uh08nyjp7.html?utm_source=stocktitan-bluesky&utm_medium=social
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
INmune Bio (NASDAQ: INMB) signed a Master Services Agreement with Uniphar Durbin Ireland to support international access and commercialization of Ebstrocel.The investigational cell therapy is being developed for recessive dystrophic epidermolysis bullosa (RDEB). INmune Bio initially plans named-patient access, allowing physician requests for individual eligible patients, in selected European countries and the Middle East and North Africa, subject to local law and country-specific statements of work. This pathway may permit access before local marketing approval. Broader distribution depends on securing regulatory approvals, pricing and reimbursement in individual countries; territorial expansion requires mutual agreement. INmune Bio believes using Uniphar’s existing infrastructure offers a capital-efficient alternative to building country-by-country capabilities.
www.stocktitan.net
October 21, 2026 at 11:00 AM
BUY $INMB (INMB.O) [StrategicCollaboration] New Collaboration; Announced @ 12:30:07Z
October 14, 2026 at 12:30 PM
#INMB #QUBT INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug…

https://www.stocktitan.net/news/INMB/i-nmune-bio-inc-and-quantum-computing-inc-partner-to-apply-quantum-7q2gwl6vj13y.html?utm_source=stocktitan-bluesky&utm_medium=social
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
INmune Bio (INMB) and Quantum Computing (QUBT) announced a collaboration to explore potential new applications for INmune Bio's investigational Alzheimer's treatment XPro. The work combines INmune Bio's preclinical research and data from four clinical trials with QCi's Dirac-3S quantum optimization machine, artificial intelligence and conventional analytics. The companies intend to identify treatment-response biomarkers and prioritize potential disease indications, with INmune Bio initially focusing on rare diseases.The Stage 1 engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets; the agreement includes options for additional work. The companies plan to compare quantum optimization with conventional statistical and machine-learning methods to test where it adds value. They also aim to establish a repeatable discovery process for additional datasets and potential indications.
www.stocktitan.net
October 14, 2026 at 12:30 PM
ICER은 QALY 증가당 2,830,387.52 CNY였다. 지불 의향(WTP) 임계값이 1인당 국내총생산(GDP)의 1배 및 3배일 때, INMB는 각각 CNY -40,066.30 및 CNY -37,141.64였습니다. 민감도 분석 및 12주 시나리오 분석 결과는 기본 시나리오의 결론을 뒷받침했다. (🧵 5/6)
October 7, 2026 at 8:28 AM
12주 이후 에레누맙 군의 결과는 치료 상태 및 중단 여부에 따라 환자 수준에서 외삽되었다. 비용에는 에레누맙 구입비, 급성기 치료제 비용, 편두통 관련 비약물적 의료 서비스 비용이 포함되었다. 결과 지표로는 총비용, 품질조정생존연수(QALY), 증분 비용-효과 비율(ICER), 증분 순금전적 이익(INMB)이 포함되었다. 단일 요인 민감도 분석, 확률적 민감도 분석, 12주 기간 시나리오 분석 및 임계 가격 분석이 수행되었다. (🧵 3/6)
October 7, 2026 at 8:28 AM
Costs included erenumab acquisition, acute medications, and migraine-related non-drug medical services. Outcomes included total costs, quality-adjusted life years (QALYs), the incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB). (🧵 5/10)
October 6, 2026 at 4:51 PM
The ICER was CNY 2,830,387.52 per QALY gained. The INMB was CNY - 40,066.30 and CNY - 37,141.64 at willingness-to-pay (WTP) thresholds of 1× and 3× Gross Domestic Product (GDP) per capita, respectively. (🧵 8/10)
October 6, 2026 at 4:51 PM
Costs included erenumab acquisition, acute medications, and migraine-related non-drug medical services. Outcomes included total costs, quality-adjusted life years (QALYs), the incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB). (🧵 5/10)
October 6, 2026 at 4:02 PM
🚨 $INMB
Clark Ronnie Duane () reported special transactions (Non-P/S).
SEC Filing: INMB
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 10:06 AM
🚨 $INMB
Clark Ronnie Duane () filed Form 3 reporting no initial stock ownership.
SEC Filing: INMB
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 10:04 AM